RESUMEN
Tumor infiltrating lymphocytes (TIL), especially T-cells, have both prognostic and therapeutic applications. The presence of CD8+ effector T-cells and the ratio of CD8+ cells to FOXP3+ regulatory T-cells have been used as biomarkers of disease prognosis to predict response to various immunotherapies. Blocking the interaction between inhibitory receptors on T-cells and their ligands with therapeutic antibodies including atezolizumab, nivolumab, pembrolizumab and tremelimumab increases the immune response against cancer cells and has shown significant improvement in clinical benefits and survival in several different tumor types. The improved clinical outcome is presumed to be associated with a higher tumor infiltration; therefore, it is thought that more accurate methods for measuring the amount of TIL could assist prognosis and predict treatment response. We have developed and validated quantitative immunohistochemistry (IHC) assays for CD3, CD8 and FOXP3 for immunophenotyping T-lymphocytes in tumor tissue. Various types of formalin fixed, paraffin embedded (FFPE) tumor tissues were immunolabeled with anti-CD3, anti-CD8 and anti-FOXP3 antibodies using an IHC autostainer. The tumor area of stained tissues, including the invasive margin of the tumor, was scored by a pathologist (visual scoring) and by computer-based quantitative image analysis. Two image analysis scores were obtained for the staining of each biomarker: the percent positive cells in the tumor area and positive cells/mm2 tumor area. Comparison of visual vs. image analysis scoring methods using regression analysis showed high correlation and indicated that quantitative image analysis can be used to score the number of positive cells in IHC stained slides. To demonstrate that the IHC assays produce consistent results in normal daily testing, we evaluated the specificity, sensitivity and reproducibility of the IHC assays using both visual and image analysis scoring methods. We found that CD3, CD8 and FOXP3 IHC assays met the fit-for-purpose analytical acceptance validation criteria and that they can be used to support clinical studies.
Asunto(s)
Biomarcadores de Tumor/análisis , Inmunohistoquímica , Inmunofenotipificación , Linfocitos Infiltrantes de Tumor/metabolismo , Linfocitos T/inmunología , Humanos , Inmunohistoquímica/métodos , Linfocitos Infiltrantes de Tumor/patología , Neoplasias/diagnóstico , Neoplasias/patología , Reproducibilidad de los ResultadosRESUMEN
Polyvalent cancer vaccines targeting the entire antigenic spectrum on tumor cells may represent a superior therapeutic strategy for cancer patients than vaccines solely directed against single Ags. In this study, we show that autologous dendritic cells (DC) transfected with RNA amplified from microdissected tumor cells are capable of stimulating CTL against a broad set of unidentified and critical prostate-specific Ags. Although the polyclonal CTL responses generated with amplified tumor RNA-transfected DC encompassed as a subcomponent a response against prostate-specific Ag (PSA) as well as against telomerase reverse transcriptase, the tumor-specific CTL were consistently more effective than PSA or telomerase reverse transcriptase CTL to lyse tumor targets, suggesting the superiority of the polyclonal response. Although tumor RNA-transfected DC stimulated CTL, which recognized not only tumor but also self-Ags expressed by benign prostate tissue, these cross-reactive CTL were exclusively specific for the PSA, indicating an immunodominant role of PSA in the prostate cancer-specific immune response. Our data suggest that tumor RNA-transfected DC may represent a broadly applicable, potentially clinically effective vaccine strategy for prostate cancer patients, which is not limited by tumor tissue availability for Ag preparation and may minimize the risk of clonal tumor escape.
Asunto(s)
Citotoxicidad Inmunológica/genética , Células Dendríticas/inmunología , Epítopos de Linfocito T/inmunología , Activación de Linfocitos/genética , Neoplasias de la Próstata/inmunología , ARN Neoplásico/inmunología , Linfocitos T Citotóxicos/inmunología , Transfección , Adyuvantes Inmunológicos/genética , Adyuvantes Inmunológicos/metabolismo , Células Cultivadas , Células Clonales , Reacciones Cruzadas/genética , Pruebas Inmunológicas de Citotoxicidad , Células Dendríticas/metabolismo , Disección , Amplificación de Genes/inmunología , Humanos , Masculino , Antígeno Prostático Específico/inmunología , Antígeno Prostático Específico/metabolismo , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/metabolismo , ARN Mensajero/inmunología , ARN Mensajero/metabolismo , ARN Neoplásico/genética , Linfocitos T Citotóxicos/metabolismo , Transcripción Genética/inmunologíaRESUMEN
BACKGROUND: Sentinel lymph node (SLN) mapping is an effective technique for staging patients with melanoma. In an attempt to avoid reinjection of radiolabeled colloid and facilitate SLN mapping at the time of surgery, we examined whether residual radioactivity from preoperative lymphoscintigraphy could be used to accurately identify SLNs during surgery 18 to 24 hours later. METHODS: Forty-six patients with newly diagnosed melanoma underwent injection of 0.22-micron filtered technetium 99m-labeled sulfur colloid followed by lymphoscintigraphy. Patients returned the next day for SLN biopsy with Isosulfan blue dye and the hand-held gamma-probe to identify SLNs. Thirty of 46 patients underwent repeat imaging before operation. No patient had reinjection of radiocolloid. RESULTS: Ninety-five SLNs were identified on initial lymphoscintigraphy, and repeat imaging on the day of surgery confirmed all SLNs previously identified. A total of 122 SLNs (2.65 per patient) were resected from 58 basins. Eighty-four (69%) of 122 SLNs stained blue, and 118 (97%) of 122 SLNs had in vivo gamma-counts greater than 4 times background. Microscopic metastases were present in 13 (10.7%) of 122 SLNs in 12 (26.1%) of 46 patients. There have been no recurrences over a mean follow-up time of 320 days. CONCLUSIONS: Intraoperative gamma-probe detection combined with blue dye injection is highly effective in identifying SLNs 18 to 24 hours after injection of 0.22-micron filtered 99mTc-sulfur colloid. Reinjection of radiocolloid is not required. This technique avoids radiopharmaceutical administration in the operating room, minimizes radiation exposure, and increases scheduling flexibility.
Asunto(s)
Ganglios Linfáticos/diagnóstico por imagen , Melanoma/patología , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Masculino , Melanoma/cirugía , Persona de Mediana Edad , Estadificación de Neoplasias , Cintigrafía , Azufre Coloidal Tecnecio Tc 99m , Factores de TiempoRESUMEN
BACKGROUND AND OBJECTIVES: Vaccination with cytokine gene-modified tumor cells augments the immune response against established tumors and protects against tumor challenges. In this study, we investigated the vaccine potential of GM-CSF-transduced MCA106 fibrosarcoma (MCA-GMCSF) cells in the C57BL/6 (B6) murine hepatic metastasis model. METHODS: Experimental mice received one to three weekly vaccines (subcutaneous/intramuscular, s.c./i.m.) of irradiated, parental, or GM-CSF-transduced MCA106 tumor cells. One week after the last immunization, hepatic metastases were established through the intrasplenic injection of live MCA106 parental (MCA106P) tumor cells. The animals were then sacrificed 3-4 weeks after surgery for evaluation of hepatic tumor burden. RESULTS: Based on in vivo experiments, both GM-CSF-modified and parental MCA106 tumor cell vaccines induced strong protection against hepatic tumor growth with grossly visible tumors rarely identified. This protection was evident even at a single vaccine dose of as low as 1x10(5) irradiated cells. Unimmunized control mice, on the other hand, consistently developed substantial hepatic tumors. Cytotoxicity assays on splenocytes (cultured in vitro for 4-5 days) showed that both groups of vaccinated mice developed strong tumor-specific cytotoxic T-lymphocyte (CTL) responses. Immunohistochemical analysis of injection sites showed infiltration of dendritic cells (DCs) and macrophages into subcutaneously injected MCA-GMCSF cells. Mostly macrophages, however, were seen at the injection site of MCA106P cells. Furthermore, the MCA106P cells expressed high levels of MHC class I antigens and the level of expression was not significantly altered by transduction with the GM-CSF gene. The high expression of MHC class I antigens probably contributed to the strong immunogenicity of the MCA106P cell vaccine. CONCLUSIONS: This study demonstrates that MCA106 parental cells are as effective as the GM-CSF-transduced cells in suppressing the growth of hepatic metastases. The cellular immune responses induced by these two vaccines, however, are probably mediated by different subsets of host effector cells. These results have important implications for the use of GM-CSF-transduced cell vaccines in the immunotherapy of tumors that have the propensity to metastasize through the lymphatic channels and the circulatory system.
Asunto(s)
Vacunas contra el Cáncer , Fibrosarcoma/patología , Factor Estimulante de Colonias de Granulocitos y Macrófagos , Inmunoterapia , Neoplasias Hepáticas/secundario , Animales , División Celular , Células Dendríticas/inmunología , Femenino , Fibrosarcoma/inmunología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/genética , Neoplasias Hepáticas/inmunología , Neoplasias Hepáticas/prevención & control , Ratones , Ratones Endogámicos C57BL , Linfocitos T/inmunología , Células Tumorales CultivadasRESUMEN
A single bolus of soluble complement (C) receptor type 1 (sCR1, TP-10) has been shown to delay hyperacute rejection (HAR) of porcine cardiac xenografts (Xgs) by primate recipients. In these recipients, C activity slowly returned and C deposition was noted in the Xgs at rejection. To evaluate the effect of sustained C inhibition using sCR1 on HAR, two additional cynomolgus monkeys received porcine cardiac Xgs and a continuous infusion of sCR1. In the first recipient, Xgs survival was 5 days (120+ hr), whereas in the second, Xg survival was 7 days (168+ hr). Serial biopsies of the Xgs were remarkable for an increasing cellular infiltrate composed predominantly of neutrophils and macrophages, and the development of edema, hemorrhage, and myocyte necrosis. These findings suggest that once C-mediated HAR has been inhibited, infiltration of the Xg by these cells may lead to accelerated acute rejection, which is an additional barrier to successful longer term Xg survival.
Asunto(s)
Proteínas Inactivadoras de Complemento , Rechazo de Injerto/prevención & control , Supervivencia de Injerto/inmunología , Trasplante de Corazón/inmunología , Receptores de Complemento/inmunología , Trasplante Heterólogo/inmunología , Animales , Trasplante de Corazón/métodos , Terapia de Inmunosupresión/métodos , Infusiones Intravenosas , Macaca fascicularis , Reperfusión Miocárdica , Porcinos , Factores de Tiempo , Trasplante Heterólogo/métodosAsunto(s)
Rechazo de Injerto/prevención & control , Trasplante de Corazón/inmunología , Receptores de Complemento 3b , Trasplante Heterólogo/inmunología , Animales , Anticuerpos Heterófilos/sangre , Proteínas del Sistema Complemento/fisiología , Inmunoglobulina G/sangre , Inmunoglobulina M/sangre , Macaca fascicularis , Masculino , Receptores de Complemento 3b/sangre , Porcinos , Factores de TiempoRESUMEN
Complement (C) inhibition alone using a recombinant soluble form of complement receptor type 1 (sCR1) prevents hyperacute rejection but not subsequent irreversible accelerated acute rejection of discordant pig-to-cynomolgus monkey cardiac xenografts, which occurs within 1 week. To inhibit accelerated acute rejection, which is associated with a rise in serum xenoreactive antibody (Ab) and a cellular infiltrate, triple therapy with standard immunosuppressive agents (cyclosporine, cyclophosphamide, and steroids [CCS]) was combined with continuous C inhibition using sCR1. Each of two monkeys that received sCR1 + CCS showed minimal evidence of rejection when killed on days 21 and 32 in comparison to a monkey that received sCR1 + subtherapeutic CCS (rejected at 11 days) and a control that received CCS alone (rejected at 38 min). Prolonged xenograft survival was associated with low Ab levels and a minimal cellular infiltrate, suggesting that combined inhibition of C, xenoreactive Ab responses, and cellular immunity may be a useful approach in overcoming the immune barriers to discordant xenotransplantation.
Asunto(s)
Proteínas Inactivadoras de Complemento/uso terapéutico , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Trasplante de Corazón/inmunología , Inmunosupresores/uso terapéutico , Receptores de Complemento/inmunología , Trasplante Heterólogo/inmunología , Animales , Anticuerpos/sangre , Formación de Anticuerpos/efectos de los fármacos , Formación de Anticuerpos/inmunología , Ciclofosfamida/uso terapéutico , Ciclosporina/uso terapéutico , Inmunidad Celular/efectos de los fármacos , Inmunidad Celular/inmunología , Macaca fascicularis , Masculino , Esteroides/uso terapéutico , PorcinosAsunto(s)
Complemento C3a/inmunología , Complemento C5a/inmunología , Rechazo de Injerto/inmunología , Trasplante de Corazón/inmunología , Proteínas de la Membrana , Trasplante Heterólogo/inmunología , Animales , Cobayas , Ratas , Receptores de Complemento/genética , Receptores de Complemento/fisiologíaAsunto(s)
Proteínas Inactivadoras de Complemento/farmacología , Rechazo de Injerto/prevención & control , Supervivencia de Injerto , Trasplante de Corazón/fisiología , Receptores de Complemento/fisiología , Trasplante Heterólogo/fisiología , Animales , Rechazo de Injerto/patología , Trasplante de Corazón/patología , Macaca fascicularis , Porcinos , Trasplante Heterólogo/patologíaRESUMEN
A critical role of the complement membrane attack complex (C5b-9) in mediating hyperacute rejection has been demonstrated previously in fully C6-deficient PVG (C-)(RT1c) rats that reject guinea pig cardiac xenografts at a delayed tempo (45 +/- 9 hr; n=16) compared with C6-sufficient PVG (C+)(RT1c) hosts (0.5 +/- 2 hr; n=6). We have investigated whether selective depletion of C6 from Lewis rats by antibody therapy prevents hyperacute rejection. A polyclonal rat-antirat C6 antibody was induced in PVG (C-) recipients by orthotopic liver transplants from congenic PVG (C+) donors. These liver grafts produced high levels of C6 that reconstituted the complement function of PVG (C-) hosts by 7 days, but the recipients responded within 28 days with the synthesis of an IgG1 antibody to rat C6. The antiserum inhibited hemolytic complement activity of Lewis (RT1(1)) rats in vivo and in vitro. The effect of C6 depletion on Xg survival was investigated by injecting Lewis rats with 2 ml of rat-antirat C6 antiserum before and 1 ml after reperfusion of the guinea pig cardiac xenograft. Lewis rats rejected guinea pig cardiac xenografts after treatment with this rat-antirat C6 antiserum in 38 +/ -11 hr (n=3). Treatment with normal control sera from PVG (C-) rats did not prolong guinea pig cardiac xenograft survival in the Lewis rats (1 +/- 0.7 hr; n=3)(P<0.0043). Injection of 3 ml of the IgG fraction purified from the rat-antirat C6 antibody (33 mg/ml) prolonged xenograft survival to 13.6 +/- 4 hr (n=4) compared with the survival of 0.61 +/- 0.3 hr (n=4) after injection of control rat IgG (33 mg/ml) (P<0.005). These results demonstrate that specific depletion of C6 by antibody therapy has a significant effect on guinea pig cardiac xenograft survival in the Lewis rat. These findings further suggest that C6 depletion may be beneficial to patients undergoing hyperacute rejection of xenografts or allografts.
Asunto(s)
Anticuerpos/fisiología , Complemento C6/deficiencia , Trasplante de Hígado/inmunología , Animales , Anticuerpos/sangre , Anticuerpos/farmacología , Anticuerpos Monoclonales/farmacología , Formación de Anticuerpos , Western Blotting , Complemento C6/inmunología , Ensayo de Actividad Hemolítica de Complemento , Supervivencia de Injerto/inmunología , Cobayas , Trasplante de Corazón , Masculino , Ratas , Ratas Endogámicas Lew , Trasplante HeterólogoAsunto(s)
Anticuerpos Monoclonales/uso terapéutico , Antígenos CD/inmunología , Supervivencia de Injerto/inmunología , Trasplante de Corazón/inmunología , Trasplante Heterólogo/inmunología , Animales , Antígenos CD18 , Rechazo de Injerto/inmunología , Rechazo de Injerto/prevención & control , Cobayas , Terapia de Inmunosupresión/métodos , Masculino , Ratas , Ratas Endogámicas , Receptores de Adhesión de Leucocito/inmunologíaRESUMEN
The use of xenografts (Xgs) from distantly related species to relieve the increasing shortage of organs for clinical transplantation is prevented by the occurrence of hyperacute rejection (HAR). This process, in which C activation plays a central role, cannot be inhibited with currently available immunosuppressants. In two clinically relevant xenotransplantation models, this study evaluated the effect of C inhibition using recombinant soluble complement receptor type 1 (sCR1) on HAR. In an ex vivo model in which porcine cardiac Xgs were perfused with human blood, cardiac function ceased within 34 min when the perfusate blood was untreated (n = 3). When the perfusate blood was treated with sCR1 (300 micrograms/ml), cardiac Xg function was maintained for up to 4 hr (n = 3). Immunohistologic examination of these Xgs demonstrated deposition of C3b/iC3b and C3d in Xgs perfused with untreated human blood but only C3d deposition in those Xgs perfused with sCR1-treated human blood. These findings are consistent with the cofactor activity of sCR1 for factor I-mediated degradation of deposited C3b/iC3b to C3d. Treatment with sCR1 also prevented the histopathologic changes of HAR observed when untreated blood was used as the perfusate. In an in vivo pig-to-primate heterotopic cardiac xenotransplantation model, in which porcine Xgs transplanted into untreated cynomolgus monkey recipients underwent HAR in 1 hr or less (n = 3), a single intravenous bolus of sCR1 (15 mg/kg) administered to the recipient immediately before Xg reperfusion markedly inhibited total and alternative pathway serum C activity and prolonged Xg survival to between 48 and 90 hr (n = 5). These studies confirm the important role of C activation in HAR of porcine cardiac Xgs by primates and indicate that sCR1 may be a useful agent for xenotransplantation.
Asunto(s)
Rechazo de Injerto/inmunología , Receptores de Complemento/fisiología , Trasplante Heterólogo/inmunología , Animales , Anticuerpos Heterófilos/sangre , Biopsia , Supervivencia de Injerto , Haplorrinos , Trasplante de Corazón/patología , Trasplante de Corazón/fisiología , Humanos , Masculino , Microscopía Fluorescente , Modelos Biológicos , Porcinos , Trasplante Heterólogo/fisiologíaRESUMEN
Xenotransplantation between phylogenetically distant species is prevented by hyperacute rejection (HAR), a process that is thought to be initiated by the binding of naturally occurring xenoreactive antibodies (NAb) to the endothelium of the xenograft (Xg) with subsequent activation of the classical pathway of C. The relative role of direct alternative pathway C activation in HAR is controversial. To evaluate the role of NAb in HAR of discordant rodent Xg, LEW rats were treated from the day of birth with i.p. injections of rabbit anti-rat IgM antiserum (RARM), or with mAb specific for rat kappa-light chain (OX12) or rat class II MHC (14-4-4S, Y-3P, or 10-2.16), in an effort to deplete B cells and NAb. These rats then underwent xenotransplantation with discordant guinea pig hearts. RARM was effective in depleting rats (n = 5) of B cells, serum IgM, and rat NAb directed against guinea pig cells, but guinea pig cardiac Xg survival was not prolonged compared with PBS-treated controls (n = 5), possibly due to the rabbit NAb specific for guinea pig cardiac tissue that were passively transferred in the RARM preparation. Of the anti-B cell mAb used to avoid this passive transfer of NAb, mAb 14-4-4S was highly effective (n = 9) in depleting the peripheral blood and spleen of B cells and the serum of IgM and NAb. Guinea pig cardiac Xg survival, however, was again not prolonged (n = 5), and rejected Xg from the B cell- and NAb-depleted recipients demonstrated rat C3 deposition in the absence of rat IgM and IgG. This study demonstrates that while neonatal anti-B cell antibody treatment can effectively deplete B cells and NAb in the rat, such treatment does not significantly prolong cardiac Xg survival in this well-established guinea pig to rat xenotransplantation model. These findings suggest that in addition to NAb depletion, inhibition of alternative C pathway activation and other humoral mechanisms may be necessary to prevent HAR and allow successful xenotransplantation.
Asunto(s)
Anticuerpos Heterófilos/metabolismo , Linfocitos B/inmunología , Rechazo de Injerto/prevención & control , Trasplante de Corazón/inmunología , Depleción Linfocítica , Enfermedad Aguda , Animales , Animales Recién Nacidos , Suero Antilinfocítico/farmacología , Proteínas del Sistema Complemento/metabolismo , Femenino , Rechazo de Injerto/etiología , Cobayas , Trasplante de Corazón/efectos adversos , Inmunización Pasiva , Inmunoglobulina M/sangre , Ratones , Ratones Endogámicos BALB C , Embarazo , Conejos , Ratas , Ratas Endogámicas Lew , Trasplante HeterólogoRESUMEN
C plays a critical role in the hyperacute rejection (HAR) of discordant xenografts (Xg), but the relative contribution of early vs late C components is unknown. In this study, genetic differences in C6 activity were correlated with HAR of guinea pig cardiac Xg by the rat. Seven rat strains were tested for C activity. Six strains (PVG.R1 (R1), PVG.1A (1A), DA, W/F, F344, LEW) had readily detectable C activity in the total and alternative pathways. Some PVG rats also had adequate C activity [PVG (C+)] but others [PVG (C-)] had a profound C6 deficiency. All rats with adequate C activity (n = 35) rejected cardiac Xg between 15 and 80 min. PVG (C+) (n = 6) rats also rejected cardiac Xg hyperacutely (26 +/- 12 min), whereas PVG (C-) (n = 16) rats, which had high preformed IgM natural antibody titers, rejected cardiac Xg in 1 to 2 days (2678 +/- 542 min). Transfer of serum from R1 rats to PVG (C-) recipients with vigorously beating Xg caused HAR of cardiac Xg within 116 +/- 75 min. Transfer of fresh PVG (C-) serum or heat-inactivated R1 serum did not induce HAR. HAR was characterized by intravascular platelet aggregation and interstitial hemorrhage, whereas Xg transplanted to PVG (C-) recipients had patent vessels at 30 min but were heavily infiltrated by granulocytes and monocytes at 2 days. These findings indicate that a deficiency in C6 prevents HAR but allows an accelerated acute rejection that may be mediated by the generation of vasoactive and chemotactic C3a and C5a.
Asunto(s)
Complemento C6/deficiencia , Rechazo de Injerto , Trasplante de Corazón/inmunología , Animales , Complemento C3/metabolismo , Complemento C5/metabolismo , Complemento C6/genética , Ensayo de Actividad Hemolítica de Complemento , Vía Alternativa del Complemento , Cricetinae , Trasplante de Corazón/efectos adversos , Trasplante de Corazón/patología , Inmunoglobulina M/metabolismo , Cinética , Masculino , Miocardio/inmunología , Miocardio/patología , Ratas , Ratas Endogámicas , Trasplante HeterólogoAsunto(s)
Proteínas del Sistema Complemento/metabolismo , Rechazo de Injerto , Trasplante de Corazón/inmunología , Animales , Anticuerpos Heterófilos/metabolismo , Cobayas , Trasplante de Corazón/efectos adversos , Masculino , Ratas , Ratas Endogámicas F344 , Ratas Endogámicas Lew , Ratas Endogámicas WF , Especificidad de la Especie , Factores de Tiempo , Trasplante HeterólogoRESUMEN
The clinical application of xenotransplantation between distantly related species is currently prevented by the occurrence of hyperacute rejection (HAR). Controversy exists over the importance of natural xenoreactive antibody (NAb)-mediated activation of the classical complement pathway vs. direct activation of the alternative C pathway in this process. In order to evaluate HAR of xenografts (Xgs) in the absence of NAb, this study utilized K strain leghorn chickens that were bursectomized (Bx) on day 17 in ovo (n = 18) to prevent B cell development and production of NAb. Aged-matched untreated siblings served as controls (n = 13). Based on pretransplant antibody levels, the Bx chickens were divided into two groups: totally Bx (Total Bx, n = 9) and partially Bx (Part Bx, n = 9). Chickens then underwent heterotopic cardiac xenotransplantation using PVG rats as donors, where the Xg was connected to the circulation of the chicken recipient utilizing cannulae. For the control group, Xg survival was 28 +/- 3 min (mean +/- SEM), while Part Bx prolonged survival to 80 +/- 15 min. Total Bx extended rat Xg survival to 102 +/- 11 min, with 5 of 9 Xgs functioning well at the time of termination of the study (90-120 min). Three chickens in the Total Bx group with rat cardiac Xgs that were functioning at 120 min were given a 1 ml i.v. injection of heat inactivated control chicken serum. This led to loss of Xg function within 10 min, confirming the important role for NAb in HAR in this species combination. Histologic examination of the Xgs following perfusion revealed significant arterial endothelial injury in the control and Part Bx groups but not in the Total Bx group. Conversely, Xgs from the Total Bx group showed marked venous congestion, which was not seen in the other two groups. This study demonstrates that: (1) Bx effectively eliminates NAb; (2) Xg survival is significantly prolonged in the absence of NAb in this rat-to-chicken xenogeneic combination; (3) the presence of NAb is associated with arterial endothelial injury; and (4) in the absence of NAb, marked venous congestion and injury occurs, which is possibly mediated by alternative C pathway activation or other humoral mechanisms.